Commercial Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool BioPharma DiveSome 1,390 Foundayo prescriptions were written in two days, according to analysts.CommercialMetabolic & GLP-1Read full story pharminent April 17, 2026 (Last updated: April 17, 2026) BioPharma Dive Some 1,390 Foundayo prescriptions were written in two days, according to analysts. CommercialMetabolic & GLP-1Read full story Post navigation Previous: Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launchNext: Kailera makes history with record-breaking $625m IPO Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
